



JOINT MASTER

# SYLLABUS

Name of the course:	Health, social protection and the pharmaceutical industry			
Teacher:	Nathalie Coutinet			
University / organisation:	Université Sorbonne Paris Nord			
Language of teaching:	English			
ECTS:	3 ECTS			
Semester (S1, S2, S3 or S4):	<input type="checkbox"/> S1	<input type="checkbox"/> S2	<input checked="" type="checkbox"/> S3	<input type="checkbox"/> S4
Teaching method(s):	<input checked="" type="checkbox"/> Lecture courses		<input checked="" type="checkbox"/> Flipped classroom	
	Other:			
Type(s) of evaluation:	<input checked="" type="checkbox"/> Sitting exam		<input checked="" type="checkbox"/> Written report	
	<input type="checkbox"/> Oral defence		<input type="checkbox"/> Group project	
	Other comments:			
Expected deadline(s) for the evaluation(s)	W19			
Expected date of final results:	W23			
Summary of the content:	<p>The objective of this course is to present and analyse:</p> <ul style="list-style-type: none"> <li>• the characteristics of the pharmaceutical industry;</li> <li>• the impact of the financialization of big pharma;</li> <li>• the history and role of patents on molecules;</li> <li>• the consequences of TRIPS in terms of access and price;</li> <li>• the production model of drugs and vaccines;</li> </ul> <p>the drug policies conducted mainly in Europe.</p>			
Indicative list of lectures:	<p>Lecture 1: Pharmaceutical industry: Key features</p> <p>Lecture 2: History of patents on drugs</p> <p>Lecture 3: Trips</p> <p>Lecture 4: The role of NGOs in access to treatment</p> <p>Lecture 5: MSF Conference</p> <p>Lecture 6: The drug production model</p> <p>Lecture 7: Health care system</p>			

## SYLLABUS

Short bibliography:

Abecassis et Coutinet, *Economie du médicament*, Repères, La Découverte, 2018.

Coriat, Orsi et d'Almeida, TRIPS and the international public health controversies: issues and challenges, *Industrial and Corporate Change*, 2006.

Jaffe, The U.S. patent system in transition: policy innovation and the innovation process, *Research Policy*, 2000.

Abecassis, Coutinet, Coriat, Leyronas, From Product Development Partnerships to the Commons DNDi Fifteen Years Later, 2018, WP9, En Communs

Wouters, Shadlen, Salcher-Konrad, Pollard, Larson, Teerawattananon, Jit Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment, *The Lancet*, 2021.